The U.S. antibody drug conjugates (ADC) market is witnessing remarkable growth, driven by the rising prevalence of cancer, technological advancements in biotechnology, and increasing investments in targeted therapies. ADCs are innovative therapeutics...

Markdown supported · ⌘↵ to post
No responses yet.